Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Ruxience

(RUK-see-ents)
A drug that contains the active ingredient rituximab and is used alone or with other drugs to treat adults with certain types of B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that are CD20 positive. It is also being studied in the treatment of other conditions and types of cancer. Ruxience binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Ruxience is a type of monoclonal antibody.
Search NCI's Dictionary of Cancer Terms